Section 26B-4-243 - Guidance for treatment with medical cannabisThe department, in consultation with the Center for Medical Cannabis Research created in Section 53B-17-1402, shall:
(1) develop evidence-based guidance for treatment with medical cannabis based on the latest medical research that shall include: (a) for each qualifying condition, a summary of the latest medical research regarding the treatment of the qualifying condition with medical cannabis;(b) risks, contraindications, side effects, and adverse reactions that are associated with medical cannabis use; and(c) potential drug interactions between medical cannabis and medications that have been approved by the United States Food and Drug Administration; and(2) educate recommending medical providers, pharmacy medical providers, medical cannabis cardholders, and the public regarding: (a) the evidence-based guidance for treatment with medical cannabis described in Subsection (1)(a);(b) relevant warnings and safety information related to medical cannabis use; and(c) other topics related to medical cannabis use as determined by the department.Added by Chapter 281, 2023 General Session ,§ 3, eff. 5/3/2023, technically renumbered for proper placement in Title and Chapter.